Announcements Trials
Browse Landscape

Phase

Phase 2 215Phase 3 64Phase 1 47Phase 1/2 40Phase 2/3 12Phase 4 6Phase NA 5Phase EARLY_PHASE1 3

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 4Gynecologic 4CNS 3Breast 3Genitourinary 2Gastrointestinal 2Sarcoma 1Lymphoid 1Head & Neck 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Letrozole 9Fluorodeoxyglucose F18 7pembrolizumab 6Magnetic Resonance Spectroscopy 6atezolizumab 5Blood Specimen Collection 5Trastuzumab 4Oncolytic Virotherapy 4Biopsy 4Bevacizumab 4palbociclib 3durvalumab 3Vitamin D 3Taxes 3Saline Solution 3Radiotherapy 3Metformin 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Albumin-Bound Paclitaxel 3pertuzumab 2olaparib 2bazedoxifene 2Vinorelbine 2Tamoxifen 2Sentinel Lymph Node Biopsy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carboplatin × Breast × Clear all
NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Recruiting
15 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT00949247 2020-07-27

Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡